BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 21198664)

  • 1. Immunization delivered by lentiviral vectors for cancer and infectious diseases.
    Hu B; Tai A; Wang P
    Immunol Rev; 2011 Jan; 239(1):45-61. PubMed ID: 21198664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo.
    Ciré S; Da Rocha S; Yao R; Fisson S; Buchholz CJ; Collins MK; Galy A
    PLoS One; 2014; 9(7):e101644. PubMed ID: 25058148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
    Dullaers M; Thielemans K
    J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral vectors for anti-tumor immunotherapy.
    Breckpot K; Emeagi PU; Thielemans K
    Curr Gene Ther; 2008 Dec; 8(6):438-48. PubMed ID: 19075627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.
    Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A
    Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward integrase defective lentiviral vectors for genetic immunization.
    Negri DR; Michelini Z; Cara A
    Curr HIV Res; 2010 Jun; 8(4):274-81. PubMed ID: 20353396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
    Lopes L; Fletcher K; Ikeda Y; Collins M
    Cancer Immunol Immunother; 2006 Aug; 55(8):1011-6. PubMed ID: 16311731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
    He Y; Zhang J; Mi Z; Robbins P; Falo LD
    J Immunol; 2005 Mar; 174(6):3808-17. PubMed ID: 15749922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral vectors for gene transfer into antigen presenting cells.
    Monahan SJ; Salgaller ML
    Curr Opin Mol Ther; 1999 Oct; 1(5):558-64. PubMed ID: 11249662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.
    Lizée G; Gonzales MI; Topalian SL
    Hum Gene Ther; 2004 Apr; 15(4):393-404. PubMed ID: 15053864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection.
    Norton TD; Tada T; Leibowitz R; van der Heide V; Homann D; Landau NR
    Mol Ther; 2020 Aug; 28(8):1795-1805. PubMed ID: 32497512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine.
    Coutant F; Frenkiel MP; Despres P; Charneau P
    PLoS One; 2008; 3(12):e3973. PubMed ID: 19096527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
    Bryson PD; Han X; Truong N; Wang P
    Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.
    Cervantes-Barragan L; Züst R; Maier R; Sierro S; Janda J; Levy F; Speiser D; Romero P; Rohrlich PS; Ludewig B; Thiel V
    mBio; 2010 Sep; 1(4):. PubMed ID: 20844609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New viral vectors for infectious diseases and cancer.
    Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
    Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy: development of immunostimulatory treatments for cancer.
    Gilligan MG; Knox PG; Searle PF
    Biotechnol Genet Eng Rev; 2000; 17():497-529. PubMed ID: 11255679
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunostimulatory DNA sequences and cancer therapy.
    Weiner GJ
    Springer Semin Immunopathol; 2000; 22(1-2):107-16. PubMed ID: 10944805
    [No Abstract]   [Full Text] [Related]  

  • 18. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells.
    Gennari F; Lopes L; Verhoeyen E; Marasco W; Collins MK
    Hum Gene Ther; 2009 Jun; 20(6):554-62. PubMed ID: 19260768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Do dendritic cells modified with retroviral vectors carrying cytokine genes become a therapeutic tool?].
    Szyda A; Rossowska J; Pajtasz-Piasecka E; Duś D
    Postepy Hig Med Dosw (Online); 2006; 60():552-62. PubMed ID: 17115005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.
    Breckpot K; Aerts JL; Thielemans K
    Gene Ther; 2007 Jun; 14(11):847-62. PubMed ID: 17361214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.